Haematologica

publication venue for

Severe delayed hemolytic transfusion reaction due to anti-Fy3 in a patient with sickle cell disease undergoing red cell exchange prior to hematopoietic progenitor cell collection for gene therapy. 2021
T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. 2003
Successful management of impending late graft failure in a thalassemic bone marrow transplant recipient. 2002
Long non-coding RNA mitophagy and ALK- anaplastic lymphoma associated transcript: a novel regulator of mitophagy in T cell lymphoma. 2023
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade? 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. 2023
Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity. 2023
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial. 2023
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.. 108. 2023
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy. 2023
The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.. 107. 2022
Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001.. 107. 2022
Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment.. 107. 2022
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.. 107. 2022
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.. 107. 2022
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.. 107. 2022
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.. 106. 2021
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma.. 106. 2021
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.. 106. 2021
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.. 106. 2021
Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.. 106. 2021
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.. 106. 2021
Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells.. 106. 2021
Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort.. 105. 2020
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?. 105. 2020
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.. 105. 2019
Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders.. 105. 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.. 105. 2019
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.. 104. 2019
Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia.. 104. 2019
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.. 104. 2019
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.. 104. 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.. 104. 2018
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results.. 103. 2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.. 103. 2018
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia.. 103. 2018
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project.. 103. 2018
Single-agent dabrafenib for BRAF^V600E-mutated histiocytosis.. 103. 2018
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results.. 103. 2018
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor.. 102. 2017
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.. 102. 2017
Bleeding risk of surgery and its prevention in patients with inherited platelet disorders.. 102. 2017
The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia.. 102. 2017
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes.. 101. 2016
Donor and recipient sex in allogeneic stem cell transplantation: what really matters.. 101. 2016
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.. 101. 2016
The European Hematology Association Roadmap for European Hematology Research: a consensus document.. 101. 2016
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.. 100. 2015
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.. 100. 2014
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.. 99. 2014
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia.. 99. 2014
Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.. 99. 2014
Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.. 99. 2014
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.. 99. 2014
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.. 99. 2014
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors.. 99. 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.. 98. 2013
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.. 99. 2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.. 98. 2013
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.. 99. 2013
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.. 98. 2013
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial.. 98. 2013
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.. 98. 2013
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.. 98. 2013
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.. 98. 2013
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.. 98. 2013
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.. 98. 2013
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.. 98. 2012
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.. 98. 2012
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.. 98. 2012
Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy.. 97. 2012
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.. 97. 2011
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.. 97. 2011
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.. 96. 2011
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type.. 95. 2010
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.. 95. 2010
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.. 95. 2010
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.. 94. 2009
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.. 93. 2008
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.. 93. 2008
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.. 93. 2008
Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta.. 93. 2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.. 93. 2008
The pattern of genomic gains in salivary gland MALT lymphomas.. 92. 2007
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.. 90. 2005
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.. 90. 2005
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.. 88. 2003
Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis.. 81. 1996
DNMT3A and stem cell function: new insights into old pathways.. 97. 2012
Immune surveillance of leukemia? 2005
Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now. 2005
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study. 2021
Acute myeloid leukemia shapes the bone marrow stromal niche in vivo. 2021
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. 2021
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. 2020
Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation. 2020
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. 2020
Expression and function of cathelicidin hCAP18/LL-37 in chronic lymphocytic leukemia. 2020
Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features? 2019
Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. 2019
Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells. 2019
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. 2019
Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. 2019
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. 2019
Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. 2019
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. 2018
Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. 2018
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies. 2018
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 2018
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. 2018
Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas. 2017
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. 2017
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. 2017
Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells. 2017
Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. 2017
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. 2016
Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients. 2016
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. 2016
Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. 2016
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. 2015
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. 2015
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. 2015
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. 2014
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. 2013
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. 2010
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. 2009
Chromosomal translocations involving BCL6 in MALT lymphoma. 2008
Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. 2005
Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. 2005
A technique for detecting leukocyte-derived free radical production. 1990
Leukemia stem cell gene expression signatures contribute to acute myeloid leukemia risk stratification.. 105. 2020
New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches.. 104. 2019
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.. 99. 2014
Extending the reach of nilotinib in chronic myeloid leukemia.. 99. 2014
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.. 99. 2014
Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations.. 99. 2014
T315I, more or less, predicts for major molecular response: the devil is in the details!. 98. 2013
Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective.. 95. 2010
Pathophysiology of Waldenström's macroglobulinemia.. 95. 2010
Towards the genetic treatment of beta-thalassemia: new disease models, new vectors, new cells.. 93. 2008
Chronic myeloid leukemia in 2006: a perspective.. 91. 2006
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? 2019
Thrombopoietin receptor agonists: ten years later. 2019
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. 2016
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. 2016
Epigenetic regulators and their impact on therapy in acute myeloid leukemia. 2016
A new prognostic score for AIDS-related lymphomas in the rituximab-era. 2014
Primary thrombocytosis in children. 2014
Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. 2011
Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. 2000
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. 1997
Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. 1990

VIVO Weill Cornell Medical College

Haematologica Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)